Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process
August 31, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food and...
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
August 30, 2018 08:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will participate in the following conferences in...
Portola Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 08:01 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2018 and provided a...
Portola Pharmaceuticals Appoints Ernie Meyer as Executive Vice President and Chief Human Resources Officer
August 09, 2018 08:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Ernie Meyer as executive vice president and chief human...
U.S. Centers for Medicare and Medicaid Services (CMS) Grants New Technology Add-On Payment for Portola Pharmaceuticals’ Andexxa
August 03, 2018 08:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has...
Portola Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
August 02, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
European CHMP Maintains Negative Opinion on Portola Pharmaceuticals’ Betrixaban Following Appeal
July 27, 2018 08:24 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 03, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 03, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on June 27, 2018, the Compensation Committee of the Board of...
Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations
June 25, 2018 08:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the appointment of Glenn Brame as senior vice president of technical...
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
June 05, 2018 16:30 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will present at the following conferences in June: ...